Centre for Infectious Disease and Control (Cib), National Institute for Public Health and the Environment, Bilthoven, The Netherlands.
Vaccine. 2011 Aug 5;29(34):5725-30. doi: 10.1016/j.vaccine.2011.05.094. Epub 2011 Jun 12.
Whooping cough, caused by Bordetella pertussis, is reemerging in the vaccinated population. Antibody levels to pertussis antigens wane rapidly after both whole-cell (wP) and acellular pertussis (aP) vaccination and protection may largely depend on long-term B- and T-cell immunity. We studied the effect of wP and aP infant priming at 2, 3, 4 and 11 months according to the Dutch immunization program on pertussis-specific memory B-cell responses before and after a booster vaccination with either a high- or low-pertussis dose vaccine at 4 years of age. Purified B-cells were characterized by FACS-analysis and after polyclonal stimulation, memory B-cells were detected by ELISPOT-assays specific for pertussis toxin, filamentous haemagglutinin and pertactin. Before and after the booster, higher memory B-cell responses were measured in aP primed children compared with wP primed children. In contrast with antibody levels, no dose-effect was observed on the numbers of memory B-cell responses. In aP primed children a fifth high-dose aP vaccination tended to induce even lower memory B-cell responses than a low-dose aP booster. In both wP and aP primed children, the number of memory B-cells increased after the booster and correlated with the pertussis-specific antibody concentrations and observed affinity maturation. This study indicates that aP vaccinations in the first year of life induce higher pertussis-specific memory B-cell responses in children 4 years of age compared with Dutch wP primary vaccinations. Since infant aP vaccinations have improved protection against whooping cough in children despite waning antibody levels, this suggests that an enhanced memory B-cell pool induction may have an important role in protection. However, the pertussis-dose of the preschool booster needs to be considered depending on the vaccine used for priming to optimize long-term protection against whooping cough.
百日咳由博德特氏菌引起,在已接种疫苗的人群中再次出现。全细胞(wP)和无细胞(aP)百日咳疫苗接种后,针对百日咳抗原的抗体水平迅速下降,保护作用可能主要依赖于长期的 B 细胞和 T 细胞免疫。我们根据荷兰免疫计划,研究了在 2、3、4 和 11 个月龄时用 wP 和 aP 对婴儿进行初级免疫,对 4 岁时用高或低剂量百日咳疫苗进行加强免疫前后百日咳特异性记忆 B 细胞反应的影响。通过流式细胞术分析对纯化的 B 细胞进行了表征,经过多克隆刺激后,通过 ELISPOT 测定法检测针对百日咳毒素、丝状血凝素和 pertactin 的记忆 B 细胞。在加强免疫前后,与 wP 初级免疫的儿童相比,aP 初级免疫的儿童测量到更高的记忆 B 细胞反应。与抗体水平相反,在记忆 B 细胞反应的数量上没有观察到剂量效应。在 aP 初级免疫的儿童中,第五次高剂量 aP 接种似乎比低剂量 aP 加强接种诱导更低的记忆 B 细胞反应。在 wP 和 aP 初级免疫的儿童中,加强免疫后记忆 B 细胞数量增加,与百日咳特异性抗体浓度和观察到的亲和力成熟相关。这项研究表明,与荷兰 wP 初级疫苗接种相比,在生命的第一年对婴儿进行 aP 接种可在 4 岁儿童中诱导更高的百日咳特异性记忆 B 细胞反应。由于婴儿 aP 接种已改善了儿童百日咳的保护作用,尽管抗体水平下降,这表明增强记忆 B 细胞池的诱导可能在保护中起着重要作用。然而,需要根据用于初级免疫的疫苗考虑学前加强免疫的百日咳剂量,以优化对百日咳的长期保护。